Peripheral Arterial Disease Trial, Recruiting (NCT06693180)

Peripheral Arterial Disease Trial, Recruiting NCT06693180 Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Condition: Peripheral Arterial Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06693180 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Arterial Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with diabetes.
People who have a diabetic foot wound or ulcer rated as moderate to severe (Grade 2 to 4 on a standard medical scale) that has been present for more than 4 weeks.
People who are able to attend follow-up visits over a full year.

Who may not be able to join:

People with severe, end-stage chronic lung disease (known as COPD at the most serious stage, called GOLD IV).
People who have received chemotherapy, medications that suppress the immune system, or steroid medications in the past 3 months.
People whose cancer has spread to other parts of the body.
People with very poor heart pumping function (where the heart is pumping at less than 20% of normal capacity) or who use an external pacemaker.
People who have recently had surgery on the chest or middle ear (confirm with trial site for exact timeframe).
People with severe epilepsy.
People with a high fever that cannot be controlled.
People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Joost R Meijering, MD, Amsterdam University Medical Center

Phone: +310205666019

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06693180

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Arterial Disease

Trial contact: +310205666019

More information: https://clinicaltrials.gov/study/NCT06693180

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with diabetes.
People who have a diabetic foot wound or ulcer rated as moderate to severe (Grade 2 to 4 on a standard medical scale) that has been present for more than 4 weeks.
People who are able to attend follow-up visits over a full year.

Who may not be able to join:

People with severe, end-stage chronic lung disease (known as COPD at the most serious stage, called GOLD IV).
People who have received chemotherapy, medications that suppress the immune system, or steroid medications in the past 3 months.
People whose cancer has spread to other parts of the body.
People with very poor heart pumping function (where the heart is pumping at less than 20% of normal capacity) or who use an external pacemaker.
People who have recently had surgery on the chest or middle ear (confirm with trial site for exact timeframe).
People with severe epilepsy.
People with a high fever that cannot be controlled.
People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Registry

ClinicalTrials.gov

Start date

1 November 2022

Est. completion

1 March 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Major amputation rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov